Past performance does not predict future results. Informational only, not investment advice.
George Sarah Catherine (Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 756.44 shares of COST at an average $1,096.01, roughly $829,065, in a Form 4 filed 2026-11-13.
Jones Teresa A. (Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 900 shares of COST at an average $1,083.95, roughly $975,558, in a Form 4 filed 2026-11-12.
Wilcox William Richard (Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 1,100 shares of COST at an average $958.20, roughly $1,054,026, in a Form 4 filed 2026-10-14.
Frates Caton (Sr. Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 800.64 shares of COST at an average $915.93, roughly $733,328, in a Form 4 filed 2026-09-30.
Adamo Claudine (Executive Vice President at COSTCO WHOLESALE CORP /NEW) reported an open-market sale of 2,200 shares of COST at an average $915.93, roughly $2,015,046, in a Form 4 filed 2026-09-30.
Costco's Ozempic/Wegovy partnership through its member prescription program at $499/month adds a low-margin, high-traffic revenue stream that strengthens the healthcare moat, increases membership renewal rates, and provides another consumption hook similar to its rotisserie chicken model. The $15B+ GLP-1 market expansion and pharmacy revenue growth (~15% y/y) support earnings durability despite current 45x valuation.
End of results.